EUVIMEDEUVIMED entdecken
Übersichtsarbeit

IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside

Sogand Vahidi, Arefeh Zabeti Touchaei, Ali Akbar Samadani

International Immunopharmacology · 2024-05 · 133 · 112156

DOI: 10.1016/j.intimp.2024.112156 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024-05. Verfasst von Sogand Vahidi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: so.vahidii@gmail.com. Hauptthemen laut MEDLINE: Interleukin-15, Killer Cells, Natural, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 153 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin 15 (IL-15) has emerged as a crucial factor in the relationship between natural killer (NK) cells and immunotherapy for cancer. This review article aims to provide a comprehensive understanding of the role of IL-15 in NK cell-mediated immunotherapy. First, the key role of IL-15 signaling in NK cell immunity is discussed, highlighting its regulation of NK cell functions and antitumor properties. Furthermore, the use of IL-15 or its analogs in clinical trials as a therapeutic strategy for various cancers, including the genetic modification of NK cells to produce IL-15, has been explored. The potential of IL-15-based therapies, such as chimeric antigen receptor (CAR) T and NK cell infusion along with IL-15 in combination with checkpoint inhibitors and other treatments, has been examined. This review also addresses the challenges and advantages of incorporating IL-15 in cell-based immunotherapy. Additionally, unresolved questions regarding the detection and biological significance of the soluble IL-15/IL-15Rα complex, as well as the potential role of IL-15/IL-15Rα in human cancer and the immunological consequences of prolonged exposure to soluble IL-15 for NK cells, are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-15Killer Cells, NaturalNeoplasmsImmunotherapyHumansAnimalsSignal TransductionImmunotherapy, Adoptive

Stichwörter der Autor:innen

CancerIL-15ImmunotherapyNK cellTumor microenvironment

Substanzen

Interleukin-15IL15 protein, human

Autor:innen und Institutionen

  • Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: so.vahidii@gmail.com.
  • Department of Chemistry, Lahijan Branch, Islamic Azad University, Lahijan, Iran.
  • Guilan Road Trauma Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran. Electronic address: a.a.hormoz@gmail.com.

Zitieren

APA

Vahidi, S., Zabeti Touchaei, A., & Samadani, A. A. (2024). IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside. International Immunopharmacology, 133, 112156. https://doi.org/10.1016/j.intimp.2024.112156

Vancouver

Vahidi S, Zabeti Touchaei A, Samadani AA. IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside. International Immunopharmacology. 2024;133:112156. doi:10.1016/j.intimp.2024.112156

BibTeX
@article{Vahidi2024,
  author = {Vahidi, Sogand and Zabeti Touchaei, Arefeh and Samadani, Ali Akbar},
  title = {IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {133},
  pages = {112156},
  doi = {10.1016/j.intimp.2024.112156}
}
Kostenlos starten →